Literature DB >> 33345351

On the properties of the toxicity index and its statistical efficiency.

Zahra S Razaee1, Arash A Amini2, Márcio A Diniz1, Mourad Tighiouart1, Greg Yothers3, André Rogatko1.   

Abstract

Cancer clinical trials typically generate detailed patient toxicity data. The most common measure used to summarize patient toxicity is the maximum grade among all toxicities and it does not fully represent the toxicity burden experienced by patients. In this article, we study the mathematical and statistical properties of the toxicity index (TI), in an effort to address this deficiency. We introduce a total ordering, (T-rank), that allows us to fully rank the patients according to how frequently they exhibit toxicities, and show that TI is the only measure that preserves the T-rank among its competitors. Moreover, we propose a Poisson-Limit model for sparse toxicity data. Under this model, we develop a general two-sample test, which can be applied to any summary measure for detecting differences among two population of toxicity data. We derive the asymptotic power function of this class as well as the asymptotic relative efficiency (ARE) of the members of the class. We evaluate the ARE formula empirically and show that if the data are drawn from a random Poisson-Limit model, the TI is more efficient, with high probability, than the maximum and the average summary measures. Finally, we evaluate our method on clinical trial toxicity data and show that TI has a higher power in detecting the differences in toxicity profile among treatments. The results of this article can be applied beyond toxicity modeling, to any problem where one observes a sparse array of scores on subjects and a ranking based on extreme scores is desirable.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Poisson-Limit model; T-rank preservation; adverse events; toxicity index; two-sample test

Year:  2020        PMID: 33345351      PMCID: PMC7953898          DOI: 10.1002/sim.8858

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  25 in total

1.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

2.  A U.S. "Cancer Moonshot" to accelerate cancer research.

Authors:  Dinah S Singer; Tyler Jacks; Elizabeth Jaffee
Journal:  Science       Date:  2016-09-07       Impact factor: 47.728

3.  Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Robert W Beart; Timothy F Wozniak; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini Soori; Janice F Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Saima Sharif; Mark S Roh; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2015-09-14       Impact factor: 13.506

Review 4.  Patient-reported outcomes and the evolution of adverse event reporting in oncology.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Ethan Basch
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

5.  Robotic compared with laparoscopic sacrocolpopexy: a randomized controlled trial.

Authors:  Jennifer T Anger; Elizabeth R Mueller; Christopher Tarnay; Bridget Smith; Kevin Stroupe; Amy Rosenman; Linda Brubaker; Catherine Bresee; Kimberly Kenton
Journal:  Obstet Gynecol       Date:  2014-01       Impact factor: 7.661

6.  Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Authors:  André Rogatko; James S Babb; Hao Wang; Michael J Slifker; Gary R Hudes
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

7.  A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer.

Authors:  R D Gelber; A Goldhirsch; B F Cole; H S Wieand; G Schroeder; J E Krook
Journal:  J Natl Cancer Inst       Date:  1996-08-07       Impact factor: 13.506

8.  Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.

Authors:  Gita Thanarajasingam; Pamela J Atherton; Paul J Novotny; Charles L Loprinzi; Jeff A Sloan; Axel Grothey
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

9.  On the properties of the toxicity index and its statistical efficiency.

Authors:  Zahra S Razaee; Arash A Amini; Márcio A Diniz; Mourad Tighiouart; Greg Yothers; André Rogatko
Journal:  Stat Med       Date:  2020-12-20       Impact factor: 2.373

10.  Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index.

Authors:  Gillian Gresham; Márcio A Diniz; Zahra S Razaee; Michael Luu; Sungjin Kim; Ron D Hays; Steven Piantadosi; Mourad Tighiouart; Greg Yothers; Patricia A Ganz; André Rogatko
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

View more
  5 in total

1.  Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.

Authors:  N Lynn Henry; Sungjin Kim; Ron D Hays; Marcio A Diniz; Michael Luu; Reena S Cecchini; Greg Yothers; André Rogatko; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2021-09-23       Impact factor: 50.717

2.  Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data.

Authors:  Vinicius F Calsavara; Márcio A Diniz; Mourad Tighiouart; Patricia A Ganz; N Lynn Henry; Ron D Hays; Greg Yothers; André Rogatko
Journal:  Qual Life Res       Date:  2022-10-17       Impact factor: 3.440

3.  Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy Tolerability.

Authors:  N Lynn Henry; André Rogatko; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2021-12-09       Impact factor: 50.717

4.  On the properties of the toxicity index and its statistical efficiency.

Authors:  Zahra S Razaee; Arash A Amini; Márcio A Diniz; Mourad Tighiouart; Greg Yothers; André Rogatko
Journal:  Stat Med       Date:  2020-12-20       Impact factor: 2.373

5.  Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data.

Authors:  Blake Langlais; Gina L Mazza; Gita Thanarajasingam; Lauren J Rogak; Brenda Ginos; Narre Heon; Howard I Scher; Gisela Schwab; Patricia A Ganz; Ethan Basch; Amylou C Dueck
Journal:  J Pain Symptom Manage       Date:  2021-08-08       Impact factor: 3.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.